Global Aspiration & Biopsy Needles Market to See Strong Growth
According to a recent report, this market will see almost seven percent annual growth over the next five years, reaching US $1.29 billion in 2026.
According to a recently released report from market research company Research and Markets, the global aspiration and biopsy needles market is poised for solid growth over the next five years. The report values the market at an estimated $879 million US for 2021, and projects it will reach $1.3 billion US in 2027, constituting a compound annual growth rate (CAGR) of 6.8 percent.
The Aspiration & Biopsy Needles Market
Aspiration and biopsy needles are used to remove tumor samples from patients for diagnosis of various cancers, as well as diagnosing wound infections and other clinical applications. There are two basic kinds of cancer needle biopsies:- Fine needle biopsy (also called fine needle aspiration, or FNA) uses a very thin, hollow needle attached to a syringe that the doctor can directly aim or guide via ultrasound or CT scan to extract a small amount of fluid and very small pieces of tissue; and
- Core needle biopsy (also called core biopsy) uses a slightly larger needle to remove a small cylinder of tissue (about 1/16 inch in diameter and 1/2 inch long).
Drivers & Patterns of Market Growth
The report suggests that growth in the biopsy and aspiration needles market will be driven by two crucial factors:- Rising cancer rates; and
- Patients’ preferences for minimally-invasive diagnostic procedures.
6 Things You Should Know about the Aspiration and Biopsy Needles Market
1. It’s expected to reach US $1.29 billion in 2026 2. Core needle biopsy is the most common type of biopsy, accounting for over 47 percent of the market in 2019 3. Hospitals accounted for 74.3 percent of the entire market in 2019 4. North America is the world's largest consumer area, accounting for 35.2 percent of global market sales in 2019 5. Europe is also a significant consumer, accounting for 30.46 percent of 2019 global sales 6. Vacuum-assisted biopsy, biopsy guns, and biopsy forceps and punches will develop at far faster rates than FNA, with CAGRs of, respectively, 3.97 percent, 3.70 percent, and 1.63 percent |
Subscribe to view Essential
Start a Free Trial for immediate access to this article